Review top news and interview highlights from the week ending June 14, 2024.
Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
Pfizer additionally noted that the trial missed the mark on key secondary end points.
The medical oncologist and clinical director of Myeloma Cellular Therapies at Dana-Farber Cancer Institute emphasized promising safety in patients with high-risk disease.
The phase 1/2 trial is proceeding to its phase 2 trial after safety was demonstrated in its first phase.
The director of the Mount Sinai Fuster Heart Hospital discussed how artificial intelligence complements data-driven research.
In observance of Myasthenia Gravis Awareness Month, held annually in June, we took a look back at a year of progress in bringing CAR-T to this autoimmune disease.